Basel Biometric Section
Basel Biometric Section of the Austro-Swiss Region of the International Biometric Society
Agenda BBS Fall Conference 2011 Current Topics in Pharmaceutical Statistics:
Dose Finding and Multiregional Trials PDF
Andy Grieve, Dose Selection in Drug Development: What Can Go Wrong? Can we put it Right?
Didier Renard, Use of modeling & simulation to support design and analysis of a new dose and regimen finding study
Björn Bornkamp, On the efficiency of two-stage adaptive designs
H.M. James Hung, Planning and Analyzing Multi-regional Clinical Trials: A Regulatory Perspective
Philip Hougaard, Global drug development strategies
Jørgen Seldrup, Designing clinical trials in a multiregional regulatory environment
Kevin J. Carroll, Consistency of treatment effect across regions in a multi-regional trial: reasonable goal or unrealistic requirement?
Agenda BBS Seminar Improving Statistical Graphics and BBS General Meeting PDF
Fabrice Bancken, General Principles, Illustrations and Wiki Resources for Improving Statistical Graphs
Further reading:
Ramon Saccilotto, Tutorial for the ggplot2 plotting system for R (based on the book by Hadley Wickham), R code
Agenda BBS Seminar Quantitative Benefit-Risk: What Matters to Whom and How? – Getting the Values and Weights Right PDF
INTRODUCTION
John Ferguson, Structured Benefit-Risk Optimization (BRO): A Framework Quantitative Decision Support Tools
Gordon Francis, Clinical Perspective on Benefit-Risk Assessments
Lawrence Phillips, Quantitative Benefit-Risk: Determining Values & Assessing Weights
Andrea Beyer, Beyond the Probability of Risk: Measuring Perception, Preferences and Values for Health States
Agenda BBS Spring Conference 2011 Comparative Quantitative Assessments: Benefit-Risk & Effectiveness PDF
Chrissie Fletcher, Industry Perspective on Comparative Effectiveness Research (CER) and the impact of Health Technology Assessment (HTA) in Europe
Melvin (Skip) Olson, Some Issues with Indirect Comparisons
Friedhelm Leverkus, Health Care Reform in Germany and Update on IQWiG Requirements
John Doyle, Effect of Comparative Effectiveness Research on Drug Development Innovation: a 360° Appraisal and Summary Discussion
Deborah Ashby, Current Methodological Approaches to Benefit-Risk Decision-Making
John Ferguson, Structured Benefit-Risk Optimization (BRO): State-of-the-art and Role of Fully Quantitative Decision Support Tools
Michael Forstner, Considerations for Implementing a Quantitative Benefit-Risk Assessment
Richard Nixon, Benefit-Risk Assessment of Multiple Sclerosis Treatments: Lessons Learnt in the use of Multi-Criteria Decision Analysis
John Doyle, Convergence of CER and BRA and Concluding Summary Discussion
Agenda BBS Spring Seminar 2011 Multiplicity in Clinical Trials PDF
Huque Mohammad, Some key multiplicity questions on primary and secondary endpoints of RCCTs and possible answers
Ferber Georg, Confirmatory statistics in PK/PD studies
Wolf Michael, Control of the false discovery rate under dependence using the bootstrap and sub sampling
Maurer Willi / Glimm Ekkehard, Multiple and repeated testing of primary, co-primary and secondary hypotheses
Agenda BBS Seminar Statistical Challenges in Biomedical Research PDF
Kalisch Markus, Can one extract causal information from high-dimensional observational data?
Sauerbrei Willi, Regression model-building with continuous variables – multivariable fractional polynomials, with extensions for interactions
Agenda BBS Seminar PDF
Harald Binder, Fitting and evaluating risk prediction models with high-dimensional molecular data
Martin Wolkewitz, Healthcare epidemiology, hospital-acquired infections, statistical modeling of outbreaks
The BBS website had to be moved. After evaluation of several possibilities we decided to give WordPress a try. BBS meeting announcements are now published in this blog.
Your feedback is most welcome.
Agenda BBS Fall 2010 Conference PDF
Ralf Bender The importance of Non-inferiority testing in benefit assessments of medical intervention
Georg Gutjahr Unblinded Sample-Size Modification for Fisher’s Exact Test
James Hung Emerging Challenges in Design and Analysis of Non-inferiority Trial
Sue-Jane Wang Adaptive Design Consideration: A Regulatory Perspective on How to Maintain Validity and Integrity of Trials
